Polatuzumab Vedotin PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
The antibody component binds CD79b on B cells and is internalised. Intracellular linker cleavage releases monomethyl auristatin E (MMAE), which binds microtubules, inhibits cell division and induces apoptosis.
Indications / reported uses
In combination regimens for adults with previously untreated diffuse large B-cell lymphoma or relapsed/refractory diffuse large B-cell lymphoma, according to the applicable product label and treatment setting.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Polatuzumab Vedotin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Polatuzumab Vedotin Permitted Daily Exposure (PDE) report (the Polatuzumab Vedotin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Polatuzumab Vedotin Occupational Exposure Limit (OEL) report (the Polatuzumab Vedotin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.